Stanley Druckenmiller Alnylam Pharmaceuticals, Inc. Transaction History

Duquesne Family Office LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $12.3 Million - $20.6 Million	88,910 New	88,910 $17.8 Million
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $7.7 Million - $10.8 Million	-63,945 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $8.13 Million - $11.1 Million	63,945 New	63,945 $10.4 Million
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $45.3 Million - $54.2 Million	-368,419 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $23.5 Million - $33.8 Million	252,250 Added 217.14%	368,419 $40.1 Million
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $8.66 Million - $14.4 Million	116,169 New	116,169 $13.4 Million

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.